CuraGen Licenses TopoTarget’s HDAC Inhibitor

By Business Review Editor

Pharma Deals Review: Vol 2004 Issue 49 (Table of Contents)

Published: 4 Jul-2004

DOI: 10.3833/pdr.v2004.i49.798     ISSN: 1756-7874

Section: Licensing

Fulltext:

Abstract

CuraGen acquired exclusive rights to develop and commercialise TopoTarget’s PXD101 (Phase I treatment for solid and hematological cancers) in Europe. TopoTarget will receive more than US$51 M for PDX101 and reciprocal royalties from CuraGen...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details